Cell Therapy Manufacturing: Challenges Remain
Executive Summary
If cell therapies are to realize their full potential, manufacturing procedures need to be in place to ensure their safety, potency and consistency at an economically sustainable cost. We aren't there yet, according to a panel at the Alliance for Regenerative Medicine's European Investor Day in London.
You may also be interested in...
Gene Therapy’s Next Big Challenge: Manufacturing
As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions.
Gene Therapy’s Next Big Challenge: Manufacturing
As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions.
Gene Therapy’s Next Big Challenge: Manufacturing
As the pipeline and market for novel cell and gene therapies expands, it is time for drug developers to address other critical aspects in the logistical chain – and for these complex therapies a lot of those issues relate to manufacturing. Looking at specific cases, In Vivo has underlined the main manufacturing challenges facing cell and gene therapy developers, and highlighted methods and approaches being used to generate solutions.